NEXTCELL PHARMA AB Inactive Instrument
NextCell Pharma AB Stock Nasdaq Stockholm
Equities
SE0009723125
Biotechnology & Medical Research
| Sales 2022 | 6.23M 567K | Sales 2023 | 13.96M 1.27M | Capitalization | 124M 11.27M |
|---|---|---|---|---|---|
| Net income 2022 | -34M -3.1M | Net income 2023 | -39M -3.55M | EV / Sales 2022 | 19.5 x |
| Net cash position 2022 | 97.12M 8.85M | Net cash position 2023 | 50.03M 4.56M | EV / Sales 2023 | 5.28 x |
| P/E ratio 2022 |
-6.32
x | P/E ratio 2023 |
-3.11
x | Employees | - |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 60.15% |
More Fundamentals
* Assessed data
More news
More press releases
| Managers | Title | Age | Since |
|---|---|---|---|
Mathias Svahn
CEO | Chief Executive Officer | 48 | 14-03-18 |
Edvard Smith
FOU | Founder | 73 | 14-03-18 |
Patrik Fagerholm
DFI | Director of Finance/CFO | 57 | 21-08-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Chairman | 83 | 13-12-31 | |
| Founder | 74 | 14-03-18 | |
Edvard Smith
FOU | Founder | 73 | 14-03-18 |
NextCell Pharma AB, formerly Cellaviva AB, is a Sweden-based biopharmaceutical company. The Company is focusing on research and development of stem cell therapies and is also running a tissue establishment and biobank, classified as healthcare provider. NextCell's business concept is to develop and commercialize mesenchymal stem cell products based on the Company's proprietary selection algorithm, primarily for the treatment of autoimmune diabetes, as well as other types of autoimmune diseases.
Calendar
2024-04-24
- Q2 2024 Earnings Release
| 1st Jan change | Capi. | |
|---|---|---|
| -1.82% | 41.35B | |
| +42.55% | 40.38B | |
| +2.56% | 39.05B | |
| -12.11% | 26.67B | |
| +3.09% | 24.07B | |
| -24.16% | 18.36B | |
| +22.12% | 11.6B | |
| -3.74% | 11.68B | |
| +7.75% | 11.15B |
